Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PAVM 
PAVmed Inc (PAVM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: PAVM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.5
1 Year Target Price $10.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -41.84% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.57M USD | Price to earnings Ratio 0.11 | 1Y Target Price 10.5 |
Price to earnings Ratio 0.11 | 1Y Target Price 10.5 | ||
Volume (30-day avg) 2 | Beta 1.08 | 52 Weeks Range 0.30 - 1.90 | Updated Date 08/29/2025 |
52 Weeks Range 0.30 - 1.90 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 4.41 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.25 | Actual -0.74 |
Profitability
Profit Margin 7144.8% | Operating Margin (TTM) -78583.34% |
Management Effectiveness
Return on Assets (TTM) -40.4% | Return on Equity (TTM) 10.67% |
Valuation
Trailing PE 0.11 | Forward PE - | Enterprise Value 43400603 | Price to Sales(TTM) 10.36 |
Enterprise Value 43400603 | Price to Sales(TTM) 10.36 | ||
Enterprise Value to Revenue 42.55 | Enterprise Value to EBITDA 0.63 | Shares Outstanding 21932900 | Shares Floating 14930482 |
Shares Outstanding 21932900 | Shares Floating 14930482 | ||
Percent Insiders 18.43 | Percent Institutions 10.64 |
Upturn AI SWOT
PAVmed Inc
Company Overview
History and Background
PAVmed Inc. is a medical device company focused on developing and commercializing minimally invasive medical technologies. Founded in 2014, it has grown through internal development and acquisitions, aiming to disrupt traditional medical procedures.
Core Business Areas
- CarpX: Minimally invasive carpal tunnel release device.
- EsoGuard/EsoCheck: Esophageal cancer detection system. EsoCheck device collects esophageal cells for analysis using the EsoGuard DNA test.
- PortIO: Implantable intraosseous vascular access device.
- DisappEAR: Resorbable pediatric ear tube.
Leadership and Structure
Lishan Aklog, M.D. serves as Chairman and CEO. The company has a typical corporate structure with a board of directors and executive management team.
Top Products and Market Share
Key Offerings
- EsoGuard/EsoCheck: Esophageal cancer detection system. EsoCheck is a cell collection device and EsoGuard is a DNA biomarker test for the early detection of Barrett's esophagus. Market share data is not publicly available. Key competitors include Exact Sciences (Cologuard, detecting colorectal cancer, has some analogous elements) and various endoscopy based diagnostics methods.
- CarpX: Minimally invasive carpal tunnel release device. This product is designed to address the large carpal tunnel release market. Market share data is not publicly available. Competitors include ConMed, Stryker, and other companies offering traditional and endoscopic carpal tunnel release systems.
- PortIO: An intraosseous vascular access system, designed as an alternative to central venous catheters. Clinical trials are underway. There is no market share currently. Teleflex is a competitor
- DisappEAR: Resorbable pediatric ear tube. This device is designed to dissolve naturally eliminating the need for removal. There is no market share data currently. Competitors include Medtronic and Summit Medical.
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, regulation, and competition. Advancements in minimally invasive techniques and diagnostics are driving growth.
Positioning
PAVmed Inc. positions itself as an innovator in minimally invasive medical technologies, targeting unmet needs and aiming to disrupt established markets.
Total Addressable Market (TAM)
TAM for PAVmed's target markets (e.g., esophageal cancer detection, carpal tunnel release) is estimated to be in the billions of dollars. PAVmed is positioned to capture a portion of this TAM through its innovative products.
Upturn SWOT Analysis
Strengths
- Innovative product pipeline
- Experienced leadership team
- Proprietary technology platforms
Weaknesses
- Limited commercialization experience
- Dependence on regulatory approvals
- History of operating losses
- Limited resources compared to larger competitors
Opportunities
- Expanding into new markets
- Strategic partnerships and acquisitions
- Favorable regulatory changes
- Increasing awareness of minimally invasive procedures
Threats
- Competition from larger medical device companies
- Technological obsolescence
- Changes in reimbursement policies
- Product liability risks
Competitors and Market Share
Key Competitors
- EXAS
- STRY
- TFX
- MDT
Competitive Landscape
PAVmed Inc. faces competition from larger, more established medical device companies. Its competitive advantage lies in its innovative technologies and focus on unmet needs.
Growth Trajectory and Initiatives
Historical Growth: PAVmed Inc's growth has been primarily driven by product development and clinical trials, rather than significant revenue generation to date.
Future Projections: Future growth projections vary and depend on factors like product approvals and adoption rates. Analyst estimates change over time.
Recent Initiatives: Recent initiatives include advancing clinical trials for PortIO, expanding the commercial reach of EsoGuard/EsoCheck, and developing new product candidates.
Summary
PAVmed Inc. is a promising medical device company with innovative technologies. It is currently loss making but has some key strengths in product development and proprietary technology. The company needs to secure regulatory approvals and successful commercialization is crucial for future growth. Competition from larger medical device companies and financing requirements are key watch items.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings (10-K, 10-Q)
- Analyst reports
- Company website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investments in small-cap companies like PAVmed Inc. are inherently risky.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PAVmed Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2016-04-28 | Chairman & CEO Dr. Lishan Aklog M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 39 | Website https://www.pavmed.com |
Full time employees 39 | Website https://www.pavmed.com | ||
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.